Effectiveness and Tolerability of Direct Acting Antiviral Therapy for Hepatitis C in a Real World Elderly Cohort

Patel, Amitkumar; Backstedt, David W.; Abidali, Hussein; Choi, Myunghan; Pedersen, Mark; Seetharam, Anil

doi:10.1016/j.cgh.2016.10.020

Cited by 4 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple prospective and retrospective real-world studies assessed the treatment efficacy of DAAs in the older age group in different countries. 20,[24][25][26][27][28][29][30][31][32][33][34][35][36][37] Most of these studies are limited by a small sample, except two studies by Su et al 26 and Lens et al 35 In the retrospective analysis from the Veteran Affairs (VA) healthcare system by Su et al, DAA regimens reported high overall SVR12 rates of 91% to 93.8% in different age subgroups of patients older than 65 years. SVR12 data were missing in 1603 patients, and the entire cohort in that study were men.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Direct‐Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States

Pan

Gayam

Rabinovich³

et al. 2019

J American Geriatrics Society

View full text Add to dashboard Cite

OBJECTIVES: Data on the virologic response and tolerability of direct-acting antivirals (DAAs) are lacking in older people because these individuals are underrepresented in clinical trials. This study aimed to assess the effectiveness and tolerability of DAA regimens in older individuals in a large cohort of real-life clinical practice. METHODS: In this retrospective study, patients with chronic hepatitis C infection between 2017 and 2018 were divided into patients aged 65 years and older and those younger than 65 years. We evaluated the sustained virologic response rates (SVRs) in both groups. Further subgroup analyses on the SVRs for patients aged 65 to 74, 75 to 84, and 85 years and older were performed. We also analyzed the predictors of treatment response in older individuals. RESULTS: Among 1151 eligible patients, 516 were in the older group and 635 were in the younger group. The overall treatment response in the entire cohort was 97.7%. A significantly higher percentage of patients presented with advanced stages of fibrosis in the older group (53.1% vs 39.5%; P = <.001). The SVR rates were similar between the two groups (98.3% vs 97.7%; P = .18). In multivariate models, age was not predictive of SVR after adjusting for confounders. Subgroup analyses in the age groups of 65 to 74, 75 to 84, and older than 85 years showed similar treatment response rates (97.4%, 97.2%, and 86.7, respectively; P = .06) and advanced fibrosis (50.8%, 61.5%, and 53.3%, respectively; P = .14). CONCLUSION: Although older people exhibit a significantly higher frequency of fibrosis, DAAs produce high rates of SVR in all age groups, and the age of the patient does not seem to have a significant impact on the efficacy of DAAs including patients in the oldest age category (≥75 y). Treatment should not be withheld in older individuals. J Am Geriatr Soc 68:379-387, 2020.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Direct‐Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States

Pan

Gayam

Rabinovich³

et al. 2019

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

“…Not surprisingly, almost 40% of them had already developed significant liver fibrosis or cirrhosis when they were first reviewed. Interferon‐free DAAs, which have been proven to be safe and effective in cirrhotic patients, should be the mainstay of therapy in patients with advanced liver disease …”

Section: Discussionmentioning

confidence: 99%

“…viewed. Interferon-free DAAs, which have been proven to be safe and effective in cirrhotic patients, should be the mainstay of therapy in patients with advanced liver disease 25. …”

mentioning

confidence: 99%

Territory‐wide population‐based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong

Hui

Wong

Fung

et al. 2018

Liver International

View full text Add to dashboard Cite

show abstract

Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey

Önlen¹,

Bal²,

Çabalak³

et al. 2022

Turk J Gastroenterol

View full text Add to dashboard Cite

Effectiveness and Tolerability of Direct Acting Antiviral Therapy for Hepatitis C in a Real World Elderly Cohort

Cited by 4 publications

References 4 publications

Efficacy of Direct‐Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States

Efficacy of Direct‐Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States

Territory‐wide population‐based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong

Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey

Contact Info

Product

Resources

About